FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2950571823> ?p ?o ?g. }

• W2950571823 endingPage "3190" @default.
• W2950571823 startingPage "3190" @default.
• W2950571823 abstract "Background. Continuous therapy, such as maintenance approach, appears to be a major therapeutic change in multiple myeloma, improving response rate and overall survival. Novel agents widen the range of treatment options, still Lenalidomide (IMiD) is widely used in this indication. Even though usually well tolerated, it remains a daily treatment, and can lead to some side effects on a long term basis. Carfilzomib, a second generation PI, allows interesting response rate and prolonged survival, with manageable adverse events. Nevertheless, only few clinical trials focused on its use in maintenance rather than in first or second line treatment. We therefore thought to study the role of 1 year Carfilzomib exposure following KMP IFM 2012-03. Methods. IFM 2012-03 is a multicenter phase I study for eNDMM (patients aged 65 years old and more) that determined the maximal tolerated dose of weekly carfilzomib, associated with melphalan and prednisone (KMP), at 70mg/m². The following results will concern the second phase of the study using intravenous Carfilzomib monotherapy in maintenance. K was administered at 36 mg/m² for 13 cycles on an every 2 weeks schedule. Results. Thirty eNDMM were recruited in IFM 2012-03. Median age is 75, with 56% R-ISS 2 or 3 and 11% high-risk cytogenetic. With K weekly from 36 to 70mg/m², ORR is reported at 93.3%, including 46.7% ≥CR ; median PFS is 35.8 months and median OS was not reached. Twenty-two (73%) patients started K maintenance and 16 (73%) completed it. Four patients progressed and 2 stopped for AEs (renal amylosis, sensory neuropahty) during the maintenance phase. At maintenance completion, 50% were ≥CR. From the start of maintenance, in landmark analysis, median PFS is 28.1 months and the estimated 36-months OS approximately 70%. Moreover, 3 patients (14%) improved their responses during maintenance. Conclusion. Carfilzomib monotherapy can be used safely in maintenance for 1 year in eNDMM, including for patients above 75 years. K maintenance may lead to deep response rate, certainly a most relevant prognostic factor for prolonged survival. Therefore, Carfilzomib maintenance, characterized with a simple administration modality, might be considered as an alternative to Lenalidomide and integrate the armamentarium of prolonged therapy in eNDMM. Further studies should still bring additional information in order to confirm our results. Disclosures Karlin: AMGEN: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Support; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Support; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees. Kolb:Amgen: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; Janssen: Other: travel and registration for my participation to international medical congres (ASH). Jaccard:Celgene: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; Pfizer: Honoraria; Abbvie: Honoraria. Belhadj:Celgene: Other: personal fees from Celgene, personal fees from Amgen, personal fees from Takeda, personal fees from Janssen, outside the submitted work. Moreau:Celgene: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria. Hulin:Janssen, AbbVie, Celgene, Amgen: Honoraria; celgene: Consultancy, Honoraria. Leleu:Karyopharm: Honoraria; Amgen: Honoraria; Carsgen: Honoraria; Incyte: Honoraria; Novartis: Honoraria; Celgene: Honoraria; Janssen: Honoraria; BMS: Honoraria; Merck: Honoraria; Sanofi: Honoraria; Takeda: Honoraria; Oncopeptide: Honoraria." @default.
• W2950571823 created "2019-06-27" @default.
• W2950571823 creator A5000761302 @default.
• W2950571823 creator A5005205127 @default.
• W2950571823 creator A5025277209 @default.
• W2950571823 creator A5025404578 @default.
• W2950571823 creator A5025996929 @default.
• W2950571823 creator A5026625329 @default.
• W2950571823 creator A5033070003 @default.
• W2950571823 creator A5036292176 @default.
• W2950571823 creator A5036677725 @default.
• W2950571823 creator A5038795221 @default.
• W2950571823 creator A5038965613 @default.
• W2950571823 creator A5043695215 @default.
• W2950571823 creator A5044238802 @default.
• W2950571823 creator A5048560248 @default.
• W2950571823 creator A5064113917 @default.
• W2950571823 creator A5069447323 @default.
• W2950571823 creator A5069449708 @default.
• W2950571823 creator A5089853890 @default.
• W2950571823 date "2019-11-13" @default.
• W2950571823 modified "2023-09-30" @default.
• W2950571823 title "Maintenance with Weekly Carfilzomib in Elderly Newly Diagnosed Multiple Myeloma (IFM 2012-03)" @default.
• W2950571823 doi "https://doi.org/10.1182/blood-2019-131793" @default.
• W2950571823 hasPublicationYear "2019" @default.
• W2950571823 type Work @default.
• W2950571823 sameAs 2950571823 @default.
• W2950571823 citedByCount "0" @default.
• W2950571823 crossrefType "journal-article" @default.
• W2950571823 hasAuthorship W2950571823A5000761302 @default.
• W2950571823 hasAuthorship W2950571823A5005205127 @default.
• W2950571823 hasAuthorship W2950571823A5025277209 @default.
• W2950571823 hasAuthorship W2950571823A5025404578 @default.
• W2950571823 hasAuthorship W2950571823A5025996929 @default.
• W2950571823 hasAuthorship W2950571823A5026625329 @default.
• W2950571823 hasAuthorship W2950571823A5033070003 @default.
• W2950571823 hasAuthorship W2950571823A5036292176 @default.
• W2950571823 hasAuthorship W2950571823A5036677725 @default.
• W2950571823 hasAuthorship W2950571823A5038795221 @default.
• W2950571823 hasAuthorship W2950571823A5038965613 @default.
• W2950571823 hasAuthorship W2950571823A5043695215 @default.
• W2950571823 hasAuthorship W2950571823A5044238802 @default.
• W2950571823 hasAuthorship W2950571823A5048560248 @default.
• W2950571823 hasAuthorship W2950571823A5064113917 @default.
• W2950571823 hasAuthorship W2950571823A5069447323 @default.
• W2950571823 hasAuthorship W2950571823A5069449708 @default.
• W2950571823 hasAuthorship W2950571823A5089853890 @default.
• W2950571823 hasConcept C126322002 @default.
• W2950571823 hasConcept C143998085 @default.
• W2950571823 hasConcept C197934379 @default.
• W2950571823 hasConcept C2776063141 @default.
• W2950571823 hasConcept C2776364478 @default.
• W2950571823 hasConcept C2778684742 @default.
• W2950571823 hasConcept C2780108899 @default.
• W2950571823 hasConcept C31760486 @default.
• W2950571823 hasConcept C535046627 @default.
• W2950571823 hasConcept C71924100 @default.
• W2950571823 hasConceptScore W2950571823C126322002 @default.
• W2950571823 hasConceptScore W2950571823C143998085 @default.
• W2950571823 hasConceptScore W2950571823C197934379 @default.
• W2950571823 hasConceptScore W2950571823C2776063141 @default.
• W2950571823 hasConceptScore W2950571823C2776364478 @default.
• W2950571823 hasConceptScore W2950571823C2778684742 @default.
• W2950571823 hasConceptScore W2950571823C2780108899 @default.
• W2950571823 hasConceptScore W2950571823C31760486 @default.
• W2950571823 hasConceptScore W2950571823C535046627 @default.
• W2950571823 hasConceptScore W2950571823C71924100 @default.
• W2950571823 hasIssue "Supplement_1" @default.
• W2950571823 hasLocation W29505718231 @default.
• W2950571823 hasOpenAccess W2950571823 @default.
• W2950571823 hasPrimaryLocation W29505718231 @default.
• W2950571823 hasRelatedWork W1965553476 @default.
• W2950571823 hasRelatedWork W2041302492 @default.
• W2950571823 hasRelatedWork W2050991415 @default.
• W2950571823 hasRelatedWork W2120529614 @default.
• W2950571823 hasRelatedWork W2136773918 @default.
• W2950571823 hasRelatedWork W2344741804 @default.
• W2950571823 hasRelatedWork W2400769328 @default.
• W2950571823 hasRelatedWork W2468113158 @default.
• W2950571823 hasRelatedWork W2581430569 @default.
• W2950571823 hasRelatedWork W2911336504 @default.
• W2950571823 hasVolume "134" @default.
• W2950571823 isParatext "false" @default.
• W2950571823 isRetracted "false" @default.
• W2950571823 magId "2950571823" @default.
• W2950571823 workType "article" @default.